The treatment of Tofacitinib for rosacea through the inhibition of the JAK/STAT signaling pathway
Archives of Dermatological Research · 2024
DOI: 10.1007/s00403-024-03314-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Dermatological Research, 2024. Verfasst von Rui Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University…. Hauptthemen laut MEDLINE: Piperidines, Pyrimidines, Rosacea, Signal Transduction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
- Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China. dongdong.zd@163.com.
- Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China. fymaweiyuan@sdsmu.edu.cn.
Zitieren
APA
Sun, R., Fan, H., Liu, J., Gao, G., Liu, C., Zhang, D., & Ma, W. (2024). The treatment of Tofacitinib for rosacea through the inhibition of the JAK/STAT signaling pathway. Archives of Dermatological Research. https://doi.org/10.1007/s00403-024-03314-4
Vancouver
Sun R, Fan H, Liu J, Gao G, Liu C, Zhang D, et al. The treatment of Tofacitinib for rosacea through the inhibition of the JAK/STAT signaling pathway. Archives of Dermatological Research. 2024. doi:10.1007/s00403-024-03314-4
BibTeX
@article{Sun2024,
author = {Sun, Rui and Fan, Huiping and Liu, Jiayun and Gao, Guomin and Liu, Chengqi and Zhang, Dong and Ma, Weiyuan},
title = {The treatment of Tofacitinib for rosacea through the inhibition of the JAK/STAT signaling pathway},
journal = {Archives of Dermatological Research},
year = {2024},
doi = {10.1007/s00403-024-03314-4}
}
EUVIMED